Biological and clinical features of the Tαβ and the Tγδ LGLL cohorts
| . | Tαβ LGLL,∗ n/N (%) . | Tγδ LGLL, n/N (%) . | P value . |
|---|---|---|---|
| Gender male | 65/129 (50.4) | 76/136 (55.9) | .3906 |
| Age > 65 y | 47/129 (36.4) | 40/136 (29.4) | .2408 |
| LGL > 2000/mm3 | 70/129 (54.3) | 24/109 (22.0) | <.0001 |
| CD16 expression | 59/129 (45.7) | 73/101 (72.3) | <.0001 |
| CD56 expression | 62/129 (48.1) | 32/103 (31.1) | .0106 |
| CD57 expression | 122/129 (94.6) | 80/102 (78.4) | .0003 |
| KIR expression | 36/129 (27.9) | 23/56 (41.1) | .0876 |
| CD158a expression | 6/129 (4.7) | 8/56 (14.3) | .0330 |
| CD158b expression | 29/129 (22.5) | 13/56 (23.2) | >.9999 |
| CD158e expression | 6/129 (4.7) | 5/56 (8.9) | .3124 |
| CD94 expression | 18/129 (14.0) | 32/75 (42.7) | <.0001 |
| NKG2A expression | 13/129 (10.1) | 12/54 (22.2) | .0355 |
| NKG2C expression | 5/129 (3.9) | 3/30 (10.0) | .1740 |
| STAT3 mutated | 39/103 (37.9) | 37/97 (38.1) | >.9999 |
| STAT5b mutated | 12/96 (12.5) | 4/94 (4.8) | .1130 |
| ANC < 1500/mm3 | 50/129 (38.8) | 65/120 (54.2) | .0161 |
| ANC < 500/mm3 | 29/129 (22.5) | 25/120 (20.8) | .7611 |
| Hb < 120 g/L | 15/129 (11.6) | 59/119 (49.6) | <.0001 |
| Hb < 90 g/L | 11/129 (8.5) | 25/119 (21.0) | .0065 |
| PLTs < 100 000/mm3 | 7/129 (5.4) | 18/119 (15.1) | .0187 |
| Splenomegaly | 22/129 (17.5) | 31/122 (21.4) | .1225 |
| Autoimmune/inflammatory diseases | 28/129 (21.7) | 49/118 (41.5) | .0009 |
| . | Tαβ LGLL,∗ n/N (%) . | Tγδ LGLL, n/N (%) . | P value . |
|---|---|---|---|
| Gender male | 65/129 (50.4) | 76/136 (55.9) | .3906 |
| Age > 65 y | 47/129 (36.4) | 40/136 (29.4) | .2408 |
| LGL > 2000/mm3 | 70/129 (54.3) | 24/109 (22.0) | <.0001 |
| CD16 expression | 59/129 (45.7) | 73/101 (72.3) | <.0001 |
| CD56 expression | 62/129 (48.1) | 32/103 (31.1) | .0106 |
| CD57 expression | 122/129 (94.6) | 80/102 (78.4) | .0003 |
| KIR expression | 36/129 (27.9) | 23/56 (41.1) | .0876 |
| CD158a expression | 6/129 (4.7) | 8/56 (14.3) | .0330 |
| CD158b expression | 29/129 (22.5) | 13/56 (23.2) | >.9999 |
| CD158e expression | 6/129 (4.7) | 5/56 (8.9) | .3124 |
| CD94 expression | 18/129 (14.0) | 32/75 (42.7) | <.0001 |
| NKG2A expression | 13/129 (10.1) | 12/54 (22.2) | .0355 |
| NKG2C expression | 5/129 (3.9) | 3/30 (10.0) | .1740 |
| STAT3 mutated | 39/103 (37.9) | 37/97 (38.1) | >.9999 |
| STAT5b mutated | 12/96 (12.5) | 4/94 (4.8) | .1130 |
| ANC < 1500/mm3 | 50/129 (38.8) | 65/120 (54.2) | .0161 |
| ANC < 500/mm3 | 29/129 (22.5) | 25/120 (20.8) | .7611 |
| Hb < 120 g/L | 15/129 (11.6) | 59/119 (49.6) | <.0001 |
| Hb < 90 g/L | 11/129 (8.5) | 25/119 (21.0) | .0065 |
| PLTs < 100 000/mm3 | 7/129 (5.4) | 18/119 (15.1) | .0187 |
| Splenomegaly | 22/129 (17.5) | 31/122 (21.4) | .1225 |
| Autoimmune/inflammatory diseases | 28/129 (21.7) | 49/118 (41.5) | .0009 |
P values are calculated using Fisher exact test. Significant P values are reported in bold.
The markedly different observation times of Tγδ LGLL and Tαβ LGLL patients prevented use of Fisher exact test for the comparison of time-dependent factors since this could lead to major bias due to lack of consideration of the time variable. Consequently, for SPMs and need for treatment, the data and the related P value were not available.
Tαβ LGLL cohort of comparable size.7